RESTON, VA (Aug. 14, 2017) – Leidos (LDOS) (NYSE: LDOS), a FORTUNE 500 science and technology company, has signed a Memorandum of Understanding (MOU) with Biosortia Pharmaceuticals to explore creating a new business relationship with a focus on identifying and advancing immuno-oncology and other immunotherapeutic opportunities.